MONROVIA, CA, August 27, 2011
/24-7PressRelease/ -- Carol A. Pratt, Ph.D. and Janet M. McNicholas, Ph.D. of K&L Gates to give a featured presentation entitled "Biosimilars: Coordinating FDA and Patent Strategies" at GTC's 4th Protein Discovery & Therapeutics Conference on Oct 19-21, 2011 in San Diego, CA
Dr's Pratt and McNicholas will discuss strategies for patenting biosimilars in conjunction with FDA regulations and how to overcome the challenges of FDA approval.
Dr. Pratt provides strategic advice regarding FDA requirements to manufacturers, distributors, importers and exporters of a wide range of medical and health products, including medical devices, drugs, dietary supplements, nutraceuticals, biologics and cosmetics. In her FDA practice, she advises clients on requirements for marketing clearance or approval, registration and listing, labeling and advertising, imports and exports, Good Clinical Practice, Good Laboratory Practice, and use of investigational drugs and devices.
Dr. McNicholas advises clients in the development and commercialization of worldwide patent portfolios. She writes and prosecutes patent applications for a broad range of life science technologies. Her practice includes conducting patentability and freedom-to-operate assessments, evaluating intellectual property, and mining both developing and mature patent portfolios for additional patenting opportunities to maximize value.
Other topics to be discussed at the conference include bi-specific and multi-specific fusion proteins, modified proteins, antibody drug conjugates, patenting strategies, non-IG scaffolds, antibody fragments, new peptide approaches, nutraceuticals, advances in expression systems, immunogenicity, aggregation, subvisible particles, stability and delivery of proteins.
Also presenting at the 4th Protein Discovery & Therapeutics Conference are organizations active in the field including Affibody, Affimed, Albany Medical College, Ambrx, Anaptysbio, Centyrex, ImmunGene, Johnson & Johnson, MacroGenics, MedImmune, Merus, Micromet AG, NCI, NIH, Nektar Therapeutics, Novartis, NovImmune SA, Pfizer, Profectus BioSciences, RC Technologies, Roche, Scripps Research Institute, Zyngenia and other experts in protein therapeutics. For more information, please visit http://www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
- antibody, approval, biobetter, biosimilar, biosimilars, biosuperior, bispecific, design, fda, immunotherapy, patent, patenting, protein, recombinant, regulations, therapeutics
Read more Press Releases from Rania Hafez:- Maureen Gibbons at BMS, to speak at Life Science Legal Strategy Conference in San Diego on June 7-8
- Brad Spellberg to speak at 9th Anti-infectives Partnering conference July 9-10, 2012 California
- Patrick Terry, Scientia Advisors, presents at Genome-wide Partnering & Deal-making, May 30-31, Boston
- Edmond Yunis to speak at Antibody Conference June 7-8, 2012 in San Diego, CA
- Gail Nunlee-Bland, MD, Howard University Hospital to speak at conference, May 15-17, in Atlanta, GA
- The Joint Commission to speak at Cardiac Centers of Excellence Conference
- Alexander Meissner to speak at 2nd Epigenetics Drug Discovery conference May 30-31, 2012 Boston, MA
- Craig C. Mello to speak at 3rd RNAi Research and Therapeutics conference May 30-31, 2012 Boston, MA
- Nathanael Gray of DFCI to Speak at the 7th Protein Kinases Conference (May 30-31, 2012 in Boston, MA)
- The Joint Commission to speak at Healthcare Centers of Excellence Summit
